Format

Send to

Choose Destination
J Perinatol. 2006 Apr;26(4):252-5.

Administration of rituximab during the first trimester of pregnancy without consequences for the newborn.

Author information

1
Département d'Hématologie, Hôpital Emile Muller, Mulhouse Cedex, France. ojedam@ch-mulhlouse.fr

Abstract

Rituximab, a chimeric mouse/human monoclonal antibody that binds to the CD20 antigen, is part of current treatment of many B-cell malignancies and several autoimmune diseases. Very few cases of rituximab administration during pregnancy have been described. We report here the case of rituximab administration during the first trimester of pregnancy in a woman with autoimmune hemolytic anemia. No significant effects were observed in B-cell counts or the immune status of the newborn.

PMID:
16570081
DOI:
10.1038/sj.jp.7211481
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center